FeesSafety
Pluang+

Galectin Therapeutics reports Q3 2026 results and updates on Phase 3 trial for liver disease drug belapectin

Company Fundamentals
16 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Galectin Therapeutics reports Q3 2026 results and updates on Phase 3 trial for liver disease drug belapectin

Galectin Therapeutics announced its financial results for Q3 2026 and provided updates on its lead drug belapectin, targeting metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis. The company submitted its Phase 3 trial protocol to the FDA, aiming for full approval, and presented positive data at a major liver disease conference. Financially, Galectin reduced its net loss to $3.6 million in Q3 2026 from $8.2 million a year earlier, with $11.7 million cash on hand and $10 million available credit. The company plans to fund operations through mid-2027 while advancing belapectin development and seeking partnerships for other cancer therapies.

Galectin Therapeutics financial results provide context for healthcare sector trends. For readers following health stocks, 67 of 150 US health-sector stocks rose and 61 fell today. Notable movers include BKD at USD 8.85 (-3.49%), TNGX at USD 24.64 (-3.37%), and GH at USD 147.01 (-3.18%), as of Nov 16, 2026 19:13 WIB.

More News

Walk assist robot market to grow 15% CAGR by 2031, driven by AI, aging population, and stroke rehab demand

Walk assist robot market to grow 15% CAGR by 2031, driven by AI, aging population, and stroke rehab demand

The global walk assist robot market is projected to grow at a 15.01% CAGR from 2024 to 2031, fueled by advances in AI, machine learning, and hybrid wearable technology. Rising stroke incidence and an aging population are increasing demand for these r...

Market News
Bullish
1 hour ago
Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

The global anti-obesity drugs market is projected to grow from USD 8.96 billion in 2026 to USD 64.96 billion by 2035, driven by a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate the market with blockbuster drugs like Mounjaro, Zepbound, and Wegov...

Bullish
1 hour ago
Sandisk announces 8-for-1 stock split effective Nov 19, focusing on flash memory prices over share count.

Sandisk announces 8-for-1 stock split effective Nov 19, focusing on flash memory prices over share count.

Sandisk will execute an 8-for-1 stock split on November 19, 2026, increasing the number of shares outstanding while reducing the price per share. Despite this split, the company emphasizes that flash memory prices remain the key factor influencing it...

Company Fundamentals
Neutral
1 hour ago
Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike is under pressure to clarify its cost-cutting plans as it prepares for its first investor day since 2017, scheduled for November 16–17. Despite efforts led by CEO Elliott Hill to turn the company around, management expects revenue to decline by ...

Market News
Bearish
1 hour ago
Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric have partnered to create North America's first plug-and-play virtual power plant (VPP) for renters and apartment residents, starting in New York City. This innovative system uses portable power stations plugged into standar...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App